■ Heru Inc., a developer of autonomous AI-powered vision diagnostics and augmentation software, has reported that tests of its re:Vive automated visual field testing platform show strong correlation with the Zeiss Humphrey Field Analyzer (HFA) when evaluating eyes in different states of health. Researchers studied 47 eyes: 21 healthy and 26 with glaucoma or other neuro-ophthalmic disease. An additional study, adding 19 normal eyes and 15 with pathology, showed similar results, according to a company news release.

The re:Vive by Heru platform enables physicians to collect vital data any time during a patient’s visit, and it is designed to fit into an existing dark room or underutilized clinical space, the manufacturer said. For patients with difficulty traveling to a doctor’s office, the unit’s diagnostic tests can also be run between practices or from remote locations, expanding access for these patients. Researchers found the re:Vive by Heru platform to be significantly faster than the HFA SITA Standard, showing an 8% gain in healthy eyes and 15% gain in eyes with pathology.

“Unlike legacy technology that requires patients to fixate on a static location for uncomfortable lengths of time, Heru’s patented ActiveTrack real-time gaze tracking confirms the patient’s fixation is always appropriate, improving data quality while keeping the patient engaged and focused throughout the exam,” said Heru chief marketing officer John Trefethen in a news release.